Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Nov 17;4:1296. doi: 10.1038/s42003-021-02773-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 6 — a Treatment regimen illustrating the schedule of delivery of anti-TGFβ (pan or isoform-specific inhibition) with either anti-CTLA-4 or anti-PD-1 therapy beginning 11 days post tumor implantation. Anti-TGFβ therapy was given via intraperitoneal injection (200 µg/mouse) every other day for a total of 8 doses. Anti-CTLA-4 (clone 9H10) was given via intraperitoneal injection (100 µg/mouse) every 3 days for a total of 3 doses. Anti-PD-1 was given via intraperitoneal injection (250 µg/mouse) every 3 days for a total of 5 doses. b Tumor growth curves for indicated treatment combinations with anti-CTLA-4. c Tumor growth curves for indicated treatment combinations with anti-PD-1. Data shown are representative of two independent experiments $\pm$ SEM. Statistics were calculated 24 days post tumor implant (n = 10 mice/group) using 2-way ANOVA. Only statistically significant differences among untreated and treated groups are shown. *p < 0.05; **p < 0.005; ***p < 0.0005; ****p < 0.0001.